Polyneuropathy, a widespread disorder affecting the peripheral nerves, arises from damage to the axon or myelin sheath. Axonal polyneuropathy, specifically involving axonal damage, is the more prevalent form, often linked to systemic illnesses, toxins, and metabolic imbalances. Accurate diagnosis is critical, and differentiating axonal polyneuropathy from other neurological conditions is paramount for effective management. This article provides a comprehensive overview of the differential diagnosis of axonal polyneuropathy.
Axonal polyneuropathy is characterized by primary damage to the nerve axon, the long, slender projection of a nerve cell that conducts electrical impulses. This contrasts with demyelinating polyneuropathies, where the myelin sheath, which insulates the axon, is the primary target. Many factors can induce axonal damage, including metabolic disorders like diabetes mellitus, toxic exposures (alcohol, heavy metals, certain medications), and nutritional deficiencies. In conditions such as diabetic neuropathy and neuropathy associated with HIV, axonal damage is the most common pathological finding. Clinically, axonal polyneuropathy typically manifests as a distal, symmetrical sensorimotor neuropathy.
The clinical presentation of axonal polyneuropathy commonly involves a gradual onset of sensory and motor deficits in a “stocking-glove” distribution, affecting the feet and lower legs initially before progressing to the hands. Patients often report numbness, tingling (paresthesia), and burning or painful sensations (dysesthesia) in their extremities. Motor symptoms emerge later and include weakness, muscle cramps, and atrophy, particularly in the intrinsic muscles of the feet and ankles. Balance and gait disturbances are common as the condition advances. Autonomic nerve involvement can also occur, leading to symptoms like early satiety, changes in bowel habits (diarrhea or constipation), erectile dysfunction, abnormal sweating, and orthostatic hypotension.
The differential diagnosis of axonal polyneuropathy requires careful consideration of other conditions that can mimic its clinical features. It is crucial to distinguish axonal polyneuropathy from other types of polyneuropathies and neurological disorders with overlapping symptoms.
Differentiating from Demyelinating Polyneuropathies: While axonal polyneuropathies are more common, demyelinating polyneuropathies, such as Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), share some symptoms but have distinct features. Demyelinating neuropathies often present with more prominent motor weakness, proximal muscle involvement, and areflexia or hyporeflexia. Nerve conduction studies are essential in differentiating these conditions. Demyelinating neuropathies typically show slowed nerve conduction velocities, conduction block, and prolonged distal latencies, whereas axonal neuropathies primarily show reduced sensory nerve action potential (SNAP) and compound muscle action potential (CMAP) amplitudes with relatively preserved or mildly slowed conduction velocities.
Small Fiber Neuropathy Considerations: Small fiber neuropathy is another important entity in the differential diagnosis. This condition selectively affects small, unmyelinated and thinly myelinated nerve fibers, leading to pain and autonomic dysfunction, often without significant motor weakness or abnormalities on routine nerve conduction studies. Patients with small fiber neuropathy typically present with burning pain, allodynia, and temperature dysregulation. Diagnosis often requires skin biopsy to assess epidermal nerve fiber density and quantitative sensory testing to evaluate small fiber function. While axonal polyneuropathy can involve small fibers, the term “small fiber neuropathy” usually refers to a condition where large fiber function is relatively spared, distinguishing it from more generalized axonal neuropathies.
Excluding Focal and Multifocal Neuropathies: Asymmetric presentations or neuropathies initiating in the upper extremities should raise suspicion for focal or multifocal neuropathies. Entrapment neuropathies, such as carpal tunnel syndrome, are focal neuropathies affecting a single nerve. Multifocal neuropathies, like vasculitic neuropathy or multifocal motor neuropathy, involve multiple nerves in a non-contiguous distribution. These conditions typically present with asymmetric weakness and sensory loss in the distribution of individual nerves, contrasting with the symmetric and distal presentation of typical axonal polyneuropathies. Electrodiagnostic studies are crucial to delineate the pattern of nerve involvement and differentiate polyneuropathies from focal or multifocal neuropathies.
Ruling Out Central Nervous System and Radiculopathies: It is also important to differentiate polyneuropathy from central nervous system lesions and radiculopathies. Upper motor neuron signs, such as hyperreflexia, spasticity, and Babinski sign, point towards central nervous system pathology rather than peripheral neuropathy. Multiple lumbosacral radiculopathies, involving nerve root compression in the spine, can sometimes mimic polyneuropathy, particularly in the lower extremities. However, radiculopathies often present with back pain, dermatomal sensory loss, and weakness in a myotomal distribution, which can help distinguish them from polyneuropathies. MRI of the spine may be necessary to evaluate for radiculopathy.
In conclusion, the differential diagnosis of axonal polyneuropathy is broad and requires a systematic approach. A thorough clinical evaluation, including neurological examination and detailed history, combined with electrodiagnostic studies, skin biopsy (when small fiber neuropathy is suspected), and appropriate imaging, are essential steps in accurately diagnosing axonal polyneuropathy and excluding other neurological conditions. Precise diagnosis is crucial for guiding appropriate management strategies and addressing the underlying causes of axonal nerve damage.
References
[1] Italian General Practitioner Study Group (IGPSG). Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Neurology. 1995;45:1832-1836. http://www.ncbi.nlm.nih.gov/pubmed/7477977?tool=bestpractice.com
[2] Bharucha NE, Bharucha AE, Bharucha EP. Prevalence of peripheral neuropathy in the Parsi community of Bombay. Neurology. 1991;41:1315-1317. http://www.ncbi.nlm.nih.gov/pubmed/1650932?tool=bestpractice.com
[3] Savettieri G, Rocca WA, Salemi G, Meneghini F, et al. Prevalence of diabetic neuropathy with somatic symptoms: a door-to-door survey in two Sicilian municipalities. Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology. 1993;43:1115-1120. http://www.ncbi.nlm.nih.gov/pubmed/8170554?tool=bestpractice.com
[4] Hanewinckel R, van Oijen M, Ikram MA, et al. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol. 2016 Jan;31(1):5-20. https://www.doi.org/10.1007/s10654-015-0094-6 http://www.ncbi.nlm.nih.gov/pubmed/26700499?tool=bestpractice.com
[5] Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology. 1993 Apr;43(4):817-24. http://www.ncbi.nlm.nih.gov/pubmed/8469345?tool=bestpractice.com
[6] Simpson DM, Kitch D, Evans SR et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology. 2006;66:1679-1687. http://www.ncbi.nlm.nih.gov/pubmed/16769940?tool=bestpractice.com
[7] Shy ME, Frohman EM, So YT, et al. Quantitative sensory testing: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003 Mar 25;60(6):898-904. https://www.doi.org/10.1212/01.wnl.0000058546.16985.11 http://www.ncbi.nlm.nih.gov/pubmed/12654951?tool=bestpractice.com
[8] Devigili G, Cazzato D, Lauria G. Clinical diagnosis and management of small fiber neuropathy: an update on best practice. Expert Rev Neurother. 2020 Sep;20(9):967-80. http://www.ncbi.nlm.nih.gov/pubmed/32654574?tool=bestpractice.com
[9] Oaklander AL, Nolano M. Scientific advances in and clinical spproaches to small-fiber polyneuropathy: A review. JAMA Neurol. 2019;76(10):1240–51 http://www.ncbi.nlm.nih.gov/pubmed/31498378?tool=bestpractice.com
[10] Devigili G, Rinaldo S, Lombardi R, et al. Diagnostic criteria for small fibre neuropathy in clinical practice and research. Brain. 2019 Dec 1;142(12):3728-36. https://academic.oup.com/brain/article/142/12/3728/5610119 http://www.ncbi.nlm.nih.gov/pubmed/31665231?tool=bestpractice.com
[11] Gondim FAA, Barreira AA, Claudino R, et al. Definition and diagnosis of small fiber neuropathy: consensus from the Peripheral Neuropathy Scientific Department of the Brazilian Academy of Neurology. Arq Neuropsiquiatr. 2018 Mar;76(3):200-8. https://www.scielo.br/j/anp/a/8zryR4hQ8HtXqTxhBd9Jn9s/?lang=en http://www.ncbi.nlm.nih.gov/pubmed/29809227?tool=bestpractice.com
[12] de Greef BTA, Hoeijmakers JGJ, Gorissen-Brouwers CML, et al. Associated conditions in small fiber neuropathy – a large cohort study and review of the literature. Eur J Neurol. 2018 Feb;25(2):348-55. https://onlinelibrary.wiley.com/doi/10.1111/ene.13508 http://www.ncbi.nlm.nih.gov/pubmed/29112785?tool=bestpractice.com
